CliffBio
small molecule

INVOKAMET XR

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Loss of exclusivityAugust 2029latest FDA-listed patent expiry
CompanyJanssen Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameINVOKAMET XR
Active ingredientCANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Strength150MG;1GM
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2016
Marketing statusRX

Listed patents

PatentExpiresType
7943582*PEDAugust 2029—
7943582February 2029substance, product
8513202*PEDJune 2028—
7943788*PEDJanuary 2028—
8513202December 2027substance, product
7943788July 2027substance, product

Regulatory exclusivity

CodeExpires
PEDJune 2028
NPPDecember 2027

More from Janssen Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

INVOKAMET XR patent cliff — loss of exclusivity August 2029 | CliffBio